The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE
George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’
George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’View Video
Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America
Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin AmericaView Video

Latest Share Chat

European Marketing Authorisation Opinion

22 May 2020 07:00

RNS Number : 6812N
Eco Animal Health Group PLC
22 May 2020
 

 

 22 May 2020

ECO Animal Health Group plc

(the "Group")

(AIM: EAH)

 

EUROPEAN POSITIVE OPINION FOR AIVLOSIN® IN PIGS

ECO Animal Health Group plc (the "Group") is pleased to announce that its subsidiary ECO Animal Health Limited (ECO) has received a positive opinion from the European Medicines Agency (EMA) for the use of Aivlosin® 625 mg/g Water Soluble Granules (WSG) for the treatment and metaphylaxis (disease control) of Mycoplasma hyopneumoniae in pigs.

Mycoplasma hyopneumoniae is the most common primary pathogen in pig respiratory disease and is a key instigator of secondary bacterial and viral pathogens.

Aivlosin®, ECO's patented antimicrobial, is used under veterinary prescription for the treatment of a variety of economically important respiratory and enteric (gut) diseases in poultry and pigs.

The European Commission is expected to issue a marketing authorisation within two months of the publication of a positive opinion.

Marc Loomes, CEO, commented: "Aivlosin® offers a safe and highly effective medication for Mycoplasma infections. This positive opinion is significant, not only in the EU which has fifteen per cent of the world's pigs but for other large international swine markets as this indication is rolled out. Whilst we bring forward our new product development programme, particularly around vaccines, it is important to note that Aivlosin® 's approved usage continues to expand across multiple treatment areas and markets."

The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). Upon the publication of this announcement via a Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.

Contacts: 

ECO Animal Health Group plc

Marc Loomes (CEO)

Christopher Wilks (CFO)

020 8447 8899

IFC Advisory

Graham Herring

Zach Cohen

020 3934 6630

N+1 Singer (Nominated Adviser & Joint Broker)

Mark Taylor

Peter Steel

Alex Bond

020 7496 3000

Peel Hunt LLP (Joint Broker)

James Steel

Dr Christopher Golden

020 7418 8900

 

ECO Animal Health Group plc ("ECO" or "the "GROUP") researches, develops and commercialises products for livestock. Our business strategy is to generate shareholder value by achieving the maximum sales potential from the existing product portfolio whilst investing in Research and Development ("R&D") for new products, particularly vaccines, and seeking to in-license new products.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCABMFTMTJTBMM

Related Shares

Back to RNS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.